Lynne and I met with the neurosurgeon at Barrow Neurological Institute yesterday. The surgeon confirms that the MRI indicates recurrent tumor. The surgeon suggested a clinical trial. Based on the trial description, I presume the clinical trial is a treatment using Cotara. Lynne’s survival to date places her in a small group of only 5 to 10% that survives glioblastoma multiforme (GBM) for more than 3 years. As a result, a continued aggressive approach is recommended. The tumor enhancement is small but all standard treatments have been used. This recommendation goes before the tumor board on Friday to reach a collective consensus on the approach and to ensure that Lynne meets the stated criteria for the clinical trial.
Cotera is a radioactively-tagged antibody that is injected through two catheters into the tumor bed over a two-day period. The theory is that the tagged antibodies attach to the cancer cells to deliver the radiation, while avoiding healthy cells.
We will learn more on Monday, 21 Jun 2010. I will post an update to provide additional details as we receive them.
Posts
1 comment:
Though I am sad to hear of the tumor's recurrance, I know that God is working great things through the process you and Lynne are going through.
I am sending prayers of thanksgiving to God for Lynne's survival, for the fantastic physicians and clinical staff working with you, and for the things learned from Lynne's journey that help others.
Sending armloads of love your way. Thank you for keeping us posted.
Lisa Hilton
Post a Comment